Clearside Biomedical Inc (NASDAQ:CLSD) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET
Company Participants
Jenny Kobin - Head of IR
George Lasezkay - President, CEO and Director
Tom Ciulla - Chief Medical Officer and Chief Development Officer
Charles Deignan - CFO
Conference Call Participants
Stacy Lee - Stifel
Rohit Bhasin - Needham & Company
Yi Chen - H.C. Wainwright
William Wood - B. Riley
Operator
Good day, and thank you for standing by. Welcome to the Clearside Biomedical Q2 2022 Financial Results and Corporate Update Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Jenny Kobin, Clearside Investor Relations. Please go ahead.
Jenny Kobin
Good morning, everyone, and thank you for joining us on the call today.
Before we begin, I would like to remind you that during today's call, we will be making certain forward-looking statements. Various remarks that we make during this call about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our annual report on Form 10-K for the year ended December 31, 2021, and our other SEC filings available on our website. In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change.
On today's call, we have George Lasezkay, our Chief Executive Officer; Dr. Thomas Ciulla, our Chief Medical Officer and Chief Development Officer; and Charlie Deignan, our Chief Financial Officer. After our formal remarks, we will open the call for your questions.
I would now like to turn the call over to George.
George Lasezkay
Thank you, Jenny. Over the last 3 months, we've made significant progress on multiple fronts. With the approval of XIPERE, the advancement of CLS-AX and broader use of our SCS Microinjector with select partners, we've created a new paradigm in retinal drug delivery. On the clinical operations side, we achieved a significant milestone by successfully completing dosing in OASIS, our CLS-AX Phase I/IIa clinical trial. CLS-AX combines the pan-VEGF inhibition from the highly potent TKI, axitinib, with targeted delivery to the affected chorioretinal tissues, utilizing our proprietary SCS Microinjector.